Bäurle Peter, Suter Andy, Wormstall Henning
Psychiatric Hospital, Münsterlingen, Switzerland.
Forsch Komplementmed. 2009 Jun;16(3):156-61. doi: 10.1159/000213167. Epub 2009 May 14.
In Chinese medicine, Ginkgo biloba is used for a variety of indications. In the current study, the safety and efficacy of a traditional fresh plant extract was investigated in patients with mild cognitive impairment.
59 elderly patients were treated for 6 weeks with a twice daily tablet containing 90 mg of fresh plant Ginkgo biloba extract. The patients suffered from age-related mild cognitive impairment of the non-Alzheimer type assessed by the DemTect score and the presence of symptoms, such as forgetfulness, memory problems, and difficulties in concentration. At the end of the treatment period, safety was primarily assessed by the occurrence of adverse events and efficacy by the DemTect score, the SF-12 quality of life questionnaire, and the change in cognitive symptoms, as well as the judgment of the investigators and patients.
At the final visit, the SF-12 mental score had increased significantly from 48.3 +/- 10.1 to 51.3 +/- 7.9, whereas the SF-12 body score (44.5 +/- 9.2 to 45.3 +/- 8.1) and the DemTect score (15.9 +/- 2.0 to 16.0 +/- 2.3) had not changed significantly. About half of all patients experienced an improvement in their memory and their ability to concentrate, as well as a decrease in symptoms of forgetfulness. The majority of investigators and patients judged the treatment to be effective. The tablets were very well tolerated and, as a treatment for their cognitive impairment, highly accepted (90% would take them again).
This newly developed, holistic fresh leaf extract of Ginkgo biloba is a safe, effective, and, at least, adjuvant treatment option for patients with mild cognitive impairments.
在中医中,银杏被用于多种适应症。在本研究中,对一种传统新鲜植物提取物在轻度认知障碍患者中的安全性和有效性进行了调查。
59名老年患者接受了为期6周的治疗,每日服用两片含90毫克新鲜银杏植物提取物的片剂。这些患者患有经DemTect评分和健忘、记忆问题及注意力不集中等症状评估的非阿尔茨海默型年龄相关性轻度认知障碍。在治疗期结束时,主要通过不良事件的发生情况评估安全性,通过DemTect评分、SF - 12生活质量问卷、认知症状的变化以及研究者和患者的判断评估有效性。
在最后一次访视时,SF - 12心理评分从48.3±10.1显著提高至51.3±7.9,而SF - 12身体评分(从44.5±9.2至45.3±8.1)和DemTect评分(从15.9±2.0至16.0±2.3)未显著变化。约一半的患者在记忆力、注意力方面有所改善,健忘症状减轻。大多数研究者和患者认为治疗有效。这些片剂耐受性良好,作为认知障碍的治疗方法,患者接受度很高(90%愿意再次服用)。
这种新开发的银杏全叶新鲜提取物是轻度认知障碍患者安全、有效的,至少是辅助治疗选择。